Mettler-Toledo International (MTD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Mar, 2026Executive summary
The annual meeting is scheduled for May 7, 2026, with shareholders voting on director elections, auditor ratification, and executive compensation approval.
Shareholders of record as of March 9, 2026, are eligible to vote, with 20,248,505 shares outstanding.
Voting can be done online, by phone, mail, or in person, and a quorum requires a majority of outstanding shares.
Voting matters and shareholder proposals
Proposals include electing nine directors for one-year terms, ratifying PricewaterhouseCoopers LLP as auditor, and an advisory vote on executive compensation.
No additional business is anticipated, but proxies may vote on other matters as needed.
Shareholder proposals and director nominations for the next annual meeting must comply with specific timing and procedural requirements.
Board of directors and corporate governance
The board consists of nine independent directors, including an independent non-executive chair and a lead director.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.
Annual board and committee self-evaluations, regular director refreshment, and mandatory retirement at age 72.
Proxy access and majority voting in uncontested elections are in place; no poison pill is in effect.
Directors must hold shares equal to five times their cash retainer within five years.
Latest events from Mettler-Toledo International
- Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 20248 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 20258 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 20248 Jul 2026 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 20258 Jul 2026 - Adjusted EPS up 9% and sales up 7% in Q1 2026, with raised full-year EPS guidance.MTD
Q1 202614 May 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026